Description: Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer " primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Home Page: www.anixa.com
3150 Almaden Expressway
San Jose,
CA
95118
United States
Phone:
408 708 9808
Officers
| Name | Title |
|---|---|
| Dr. Amit Kumar Ph.D. | CEO, Chairman & Co-Chair of CBAB |
| Mr. Michael J. Catelani CPA, MBA | President, COO, CFO & Corporate Secretary |
| Mr. John Roop | Senior Vice President of Engineering |
| Dr. Pamela D. Garzone Ph.D. | Chief Development Officer & Chair Breast Cancer Clinical Advisory Board |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.6938 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 4 |